NYSEAMERICAN:MAIA MAIA Biotechnology Q3 2024 Earnings Report $1.23 -0.03 (-2.00%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings History MAIA Biotechnology EPS ResultsActual EPS-$0.11Consensus EPS -$0.32Beat/MissBeat by +$0.21One Year Ago EPSN/AMAIA Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMAIA Biotechnology Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateMonday, November 11, 2024Conference Call Time6:00PM ETUpcoming EarningsMAIA Biotechnology's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MAIA Biotechnology Earnings HeadlinesMAIA Biotechnology, Inc. berichtet über Fortschritte in der zulassungsrelevanten Phase-3-Studie bei fortgeschrittenem nicht-kleinzelligem LungenkrebsSeptember 23 at 8:22 PM | de.marketscreener.comDMAIA Biotechnology, Inc. erhält behördliche Genehmigungen für den Start der Patientenrekrutierung für die zulassungsrelevante Phase-3-Studie THIO-104 in Spanien und PortugalSeptember 23 at 8:22 PM | de.marketscreener.comDDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 25 at 1:00 AM | Stansberry Research (Ad)MAIA Biotechnology, Inc. Receives Regulatory Approval To Begin Screening Patients For Pivotal Phase 3 THIO-104 Clinical Trial In Spain And PortugalSeptember 23 at 3:21 PM | marketscreener.comMMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and PortugalSeptember 23 at 9:17 AM | globenewswire.comMAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung CancerSeptember 22 at 7:49 PM | rttnews.comSee More MAIA Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email. Email Address About MAIA BiotechnologyMAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research centers on telomeres, protective structures at the ends of chromosomes that are maintained in many cancer cells through telomerase activity. MAIA’s lead investigational product is THIO, also known as 6-thio-2’-deoxyguanosine (6-thio-dG). The compound is designed to be activated in telomerase-positive cancer cells, promoting telomere dysfunction and DNA damage that may lead to cancer-cell death. The company is also evaluating THIO in combination with immune checkpoint inhibitors. MAIA has advanced THIO into clinical development, including the THIO-101 Phase 2 study evaluating the therapy in patients with previously treated non-small cell lung cancer. The company is headquartered in Chicago, Illinois, and is led by co-founder and Chief Executive Officer Vlad Vitoc.View MAIA Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
